| Document Type
|
:
|
BL
|
| Record Number
|
:
|
518044
|
| Doc. No
|
:
|
b360170
|
| Main Entry
|
:
|
Mauskopf, Josephine.
|
| Title & Author
|
:
|
Budget-Impact Analysis of Health Care Interventions : : A Practical Guide
|
| Publication Statement
|
:
|
Cham :: Springer International Publishing,, 2017
|
| Page. NO
|
:
|
1 online resource (234 pages)
|
| ISBN
|
:
|
9783319504827
|
|
|
:
|
: 3319504827
|
| Notes
|
:
|
Description based upon print version of record
|
|
|
:
|
6.2.1 Acute Conditions or Chronic Conditions Where Changes Occur Almost Immediately
|
| Contents
|
:
|
Author Contributions; Foreword; Preface; Abbreviations; Contents; Chapter 1: Introduction to Budget-Impact Analysis; 1.1 What Is Budget-Impact Analysis?; 1.2 Budget-Impact Analyses Compared with Cost-Effectiveness Analyses; 1.3 Uses of Budget-Impact Analyses; 1.4 Guidelines for Budget-Impact Analyses; 1.5 Overview of Chapters in This Book; Exercises; References; Chapter 2: Determining the Analytic Framework; 2.1 Eligible Population in Jurisdiction; 2.1.1 Impact of Positioning of the New Drug Within the Current Treatment Pathway on Eligible Population Size
|
|
|
:
|
2.1.2 Impact of Regulatory Approval on Eligible Population Size2.1.3 Impact of Reimbursement Decisions on Eligible Population Size; 2.1.4 Impact of New Drug Attributes on Initial Population Size; 2.1.5 Impact of New Drug Attributes on Population Size Over Model Time Horizon; 2.2 Budget Holder Time Horizon; 2.3 Potential Use of the New Drug Within the Treatment Mix; 2.4 Budget Holder Cost Perspective; 2.4.1 Service Delivery Cost Versus Reimbursement Rate; 2.4.2 Fixed Versus Variable Costs; 2.4.3 Cost Categories of Interest; 2.5 Compilation of Analytic Framework; Exercises; References
|
|
|
:
|
Chapter 3: Estimating the Diagnosed, Treated, and Eligible Population3.1 Incident and Prevalent Populations; 3.2 Estimating the Eligible Population Size; 3.3 Data for Identifying the Eligible Population; 3.4 Estimating Population Size by Subgroup; 3.5 Changing Size of the Eligible Population Over the Analysis Time Horizon; 3.5.1 Changing Population Size Regardless of Introduction of the New Drug; 3.5.2 Changing Population Size and Condition Severity Mix due to the Introduction of the New Drug; 3.6 Including Catch-Up Effects for the Prevalent Population
|
|
|
:
|
3.7 Which Eligible Population Should We Include in the Budget-Impact Analysis?Exercises; References; Chapter 4: Estimating the Treatment Mix; 4.1 Treatment Shares Without the New Drug in the Treatment Mix; 4.2 Treatment Shares with the New Drug in the Treatment Mix; 4.3 Which Treatment Shares Should We Include in the Budget-Impact Analysis?; Exercises; Reference; Chapter 5: Estimating Treatment-Related Costs; 5.1 Costs for Drug Acquisition; 5.1.1 Co-payments and Coinsurance; 5.1.2 Dispensing Fees; 5.1.3 Dose Levels; 5.1.4 Duration of Treatment; 5.2 Costs for Administering the Drug
|
|
|
:
|
5.3 Costs for Diagnostic Tests to Determine Eligibility for the Drug5.4 Costs for Monitoring the Drug for Safety and Efficacy; 5.5 Costs for Treating Side Effects Associated with the Drug; 5.6 Accounting for Differing Treatment Costs in the First and Subsequent Treatment Years; 5.7 Accounting for Other Treatment Costs; 5.8 Estimating Resource Use Changes with the New Drug; Exercises; References; Chapter 6: Estimating Condition-Related Costs; 6.1 Why the New Drug Might Change Condition-Related Costs; 6.2 Estimating Changes in Condition-Related Costs for Incident Populations
|
| Subject
|
:
|
Medical economics.
|
| Subject
|
:
|
Medical records_xData processing
|
| Dewey Classification
|
:
|
362.1
|
| LC Classification
|
:
|
R1
|
| Added Entry
|
:
|
Earnshaw, Stephanie R.
|
|
|
:
|
Brogan, Anita
|
|
|
:
|
Wolowacz, Sorrel.
|
|
|
:
|
Brodtkorb, Thor-Henrik.
|
| Added Entry
|
:
|
Ohio Library and Information Network.
|